Reply to "Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma"

J Allergy Clin Immunol Pract. 2022 Jul;10(7):1936. doi: 10.1016/j.jaip.2022.04.018.

¹ Department of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: k.a.eger@amsterdamumc.nl.
² Department of Clinical Pharmacy and Pharmacology, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
³ Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
⁴ Department of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

No abstract available

Publication types